Bariatric surgery in patients with obesity and end-stage heart failure with left ventricular assist devices: a brief guide DOI Open Access

Steven T. Em,

Manish Parikh, Babak J. Orandi

и другие.

Metabolism and Target Organ Damage, Год журнала: 2024, Номер 4(4)

Опубликована: Окт. 6, 2024

The prevalence of obesity is increasing worldwide, leading to a rise in several comorbidities, and itself an important risk factor for heart failure. Patients with end-stage failure are often not eligible transplantation (HT) instead receive cardiac support from left ventricular assist devices (LVAD). In the absence other contraindications, patients who on LVAD can lose enough weight later qualify HT. Bariatric surgery had been explored as approach loss this patient population was found be safe effective option. One recent systematic review meta-analysis has shown 67.4% able listed after bariatric subsequent (95%CI: 0.477-0.871). Of these, 32.5% would go transplant 0.201-0.448). There were also numerous cases whose function improved such that they delisted HT some removal their LVAD. many perioperative considerations when evaluating LVADs surgery. However, careful selection by multidisciplinary team mindful preparation, have opportunity longer years life.

Язык: Английский

Antiobesity Medications in Patients With Heart Failure DOI

Sureya F Hussani,

Kelly Nguyen,

Ka Man Yu

и другие.

JACC Heart Failure, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Therapeutic Ketosis for Heart Failure: A State-of-the-Art-Review DOI Creative Commons

Nandan Kodur,

Christopher Nguyen, W.H. Wilson Tang

и другие.

Journal of Cardiac Failure, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Heart failure is characterized by an energy-deprived heart, and in recent years it has been found that the failing heart increases ketone body oxidation to meet its energy demands. Accumulating evidence suggests this metabolic adaptation cardioprotective, suggesting interventions boost blood levels could aid heart. Indeed, multiple small clinical trials with short-term follow up have demonstrated supplying exogenous bodies may improve myocardial function across various manifestations of failure. As such, therapeutic ketosis, which a state are mildly elevated, great potential ameliorate Therapeutic ketosis can be achieved endogenously via exercise or dietary practices, exogenously supplementation bodies, pharmacologically treatment sodium-glucose cotransporter-2 inhibitor. Although ketosis-inducing practices cannot routinely recommended patients at time due lack robust data regarding long-term benefits risks, anecdotal some begun adopt so important for clinicians aware how optimally manage who ketosis. In review, we discuss metabolism failure, current framework distinguish between pathologic ketoacidosis, practical considerations managing adhering practices.

Язык: Английский

Процитировано

0
Treatment options for heart failure in individuals with overweight or obesity: a review DOI
Athina Nasoufidou, Panagiotis Stachteas,

Paschalis Karakasis

и другие.

Future Cardiology, Год журнала: 2025, Номер unknown, С. 1 - 15

Опубликована: Март 18, 2025

Obesity and heart failure are interlaced global epidemics, each contributing to significant morbidity mortality. is not only a risk-factor for failure, but also complicates its management, by distinctive pathophysiological mechanisms cumulative comorbidities, requiring tailored treatment plan. To present current options in individuals with overweight/obesity, emphasizing available pharmacological therapies, non-pharmacological strategies, the management of related comorbidities. We conducted comprehensive literature review regarding results treatments including cornerstone interventions as well emerging therapeutic options. Specific drug classes, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 have demonstrated consistent efficacy irrespective body mass index, while diuretics remain key fluid management. Glucagon-like peptide-1 agonists shown promising improving relevant outcomes warrant further research. Non-pharmacological approaches, weight-loss strategies lifestyle modifications, improve symptoms, exercise tolerance quality life. Managing overweight/obesity requires multidisciplinary, individualized approach integrating Emerging therapies preventive arise address unique challenges this population provide improved outcomes.

Язык: Английский

Процитировано

0
Impact of Lifestyle Modifications Along With Pharmacological Treatment of Heart Failure: A Narrative Review DOI Open Access

Elizabeth Caroline Palaparthi,

Priyanka Kanth,

Arockiamary Ignasimuthu

и другие.

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. While pharmacological therapy is foundational, lifestyle modifications are increasingly recognised for their complementary role. This narrative review explores the synergistic effects interventions, combined with treatment, in HF management. A literature search (2000-2025) was conducted using PubMed, Scopus, Cochrane, Google Scholar, to identify studies on integrative approaches care. Lifestyle changes, such as dietary modification, exercise, weight management, smoking alcohol cessation, psychosocial support, enhance efficacy standard therapies, improve quality life, reduce hospitalisations. Integration medications, like renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, sodium-glucose cotransporter-2 (SGLT2) shows improved neurohormonal balance, reduced inflammation, better endothelial function, delayed cardiac remodelling. However, socioeconomic cultural barriers challenge real-world implementation. Combining interventions pharmacotherapy provides holistic, patient-centred strategy Future efforts should focus personalised care, multidisciplinary teams, policy adherence outcomes.

Язык: Английский

Процитировано

0
Obesity and heart failure—the role of GLP-1 receptor agonists DOI
Gregor Simonis, Ulrike Schatz

Herz, Год журнала: 2025, Номер unknown

Опубликована: Апрель 2, 2025

Язык: Английский

Процитировано

0
Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy) DOI Creative Commons
Morten Malmborg, Mohamad El‐Chouli, Camilla Fuchs Andersen

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Май 6, 2025

Background Obesity is common in heart failure with reduced ejection fraction (HFrEF). As anti-obesity treatments advance, understanding how body mass index (BMI) affects outcomes HFrEF increasingly important. Objective To examine whether a BMI >27 kg/m² linked to higher risks of all-cause mortality, cardiovascular death, and (HF) hospitalization patients. Methods This study included 1,017 clinically stable, medically optimized patients from the NorthStar (2005–2009), followed through 2023 using Danish registries. Outcomes were assessed Cox models adjusted for prognostic factors. The primary endpoint was mortality; secondary endpoints HF hospitalization, composite mortality or hospitalization. Subgroup analyses compared categories (<24, 24–27, kg/m²). Results Patients had more diabetes (27.8% vs. 17.7%) lower NT-proBNP (median 776 1,163 pg/mL) than those similar etiology. Over median 8.8 years, 821 (80.7%) died, including 444 deaths, 740 (72.8%) hospitalized HF. A 35 27 associated non-significant increased (HR 1.18, 95% CI 0.94–1.48) but significantly 1.42, 1.05–1.92), 1.33, 1.05–1.67), outcome 1.30, 1.06–1.60). analysis showed 24–27 ischemic cardiomyopathy 1.31, 1.05–1.64), not non-ischemic 0.86, 0.66–1.12), interaction p=0.015. Conclusion Among patients—especially cardiomyopathy—BMI worse outcomes, challenging “obesity-survival paradox” highlighting importance effective weight management.

Язык: Английский

Процитировано

0
Role of Bariatric Surgery in Patients with Advanced Heart Failure DOI
Darae Kim, In‐Cheol Kim, Jong‐Chan Youn

и другие.

Surgery for Obesity and Related Diseases, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0
Emerging Role of Weight-Loss Medications in the Management of Heart Failure: Current Evidence and Future Perspectives DOI

Maryam Maryam,

Treesa P. Varghese,

Bachi Tazneem

и другие.

American Journal of Cardiovascular Drugs, Год журнала: 2025, Номер unknown

Опубликована: Май 28, 2025

Язык: Английский

Процитировано

0
Bariatric surgery in patients with obesity and end-stage heart failure with left ventricular assist devices: a brief guide DOI Open Access

Steven T. Em,

Manish Parikh, Babak J. Orandi

и другие.

Metabolism and Target Organ Damage, Год журнала: 2024, Номер 4(4)

Опубликована: Окт. 6, 2024

The prevalence of obesity is increasing worldwide, leading to a rise in several comorbidities, and itself an important risk factor for heart failure. Patients with end-stage failure are often not eligible transplantation (HT) instead receive cardiac support from left ventricular assist devices (LVAD). In the absence other contraindications, patients who on LVAD can lose enough weight later qualify HT. Bariatric surgery had been explored as approach loss this patient population was found be safe effective option. One recent systematic review meta-analysis has shown 67.4% able listed after bariatric subsequent (95%CI: 0.477-0.871). Of these, 32.5% would go transplant 0.201-0.448). There were also numerous cases whose function improved such that they delisted HT some removal their LVAD. many perioperative considerations when evaluating LVADs surgery. However, careful selection by multidisciplinary team mindful preparation, have opportunity longer years life.

Язык: Английский

Процитировано

1